Citron's Andrew Left: I Bought Valeant Shares as a Trade

The transcript discusses stock valuation, focusing on a specific drugmaker's worth and trading strategies. It highlights the challenges of predicting market trends based on prescription and reimbursement data. The conversation shifts to the pharmaceutical industry, differentiating between 'Good Pharma' and 'Bad Pharma' companies, with examples like Valiant and Mallinckrodt. The discussion concludes with an analysis of Valiant's market position and the complexities of investing in such stocks.

What is the speaker's opinion on Mallinckrodt and its stock performance?

What does the speaker suggest about making trades in the current market?